ABOUT US
We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.
Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.
QUALITY
As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.
WHO WE ARE
We deliver pharma products from Switzerland and from all over the world.
Our team in ELIXI International has a solid experience in the distribution of medical products.
History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.
NEWS
Lokelma (sodium zirconium cyclosilicate) approved by FDA for the treatment of hyperkalaemia
The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults…
FDA approves Aimovig ( erenumab-aooe), a preventive treatment for migraine
The U.S. Food and Drug Administration has approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment…
European Commission approves Ipsen’s Cabometyx (cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
The European Commission has approved Ipsen's Cabometyx™ (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell…
FDA approves Retacrit, first epoetin alfa biosimilar for the treatment of anemia
The U.S. Food and Drug Administration has approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the…
New indication approved by EMA for Yervoy (ipilimumab)
On 26 April 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the…
FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
On May 11 the U.S. Food and Drug Administration approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children…
FDA approves new uses for Tafinlar( dabrafenib) and Mekinist (trametinib) administered together for the treatment of BRAF-positive anaplastic thyroid cancer
The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid…
Janssen announces DARZALEX (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved…
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
On May 1 Novartis announced that the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion…
FDA approves dabrafenib (Tafinlar) plus trametinib (Mekinist) for adjuvant treatment of melanoma with BRAF V600E or V600K mutations
On April 30, 2018, the Food and Drug Administration granted regular approval to dabrafenib (TAFINLAR, Novartis Pharmaceuticals Corp.) and trametinib…
CONTACT US
ELIXI International SA
Piazza Boffalora 4
6830 Chiasso / Switzerland
Tel: +41 91 682 20 40